Kymera Therapeutics Inc. (NASDAQ:KYMR) is one of the best high-beta stocks to buy now. The company currently commands an optimistic outlook, with management remaining confident in achieving key clinical endpoints and biomarker data.
This confidence was visible on September 3, when the company presented at Citi’s ‘Biopharma Back to School’ Conference and outlined the progress across its targeted protein degradation (TPD) platform. Kymera Therapeutics Inc. (NASDAQ:KYMR) highlighted pipeline updates, with its lead asset, KT-4621, advancing into Phase 2 trials for atopic dermatitis and asthma.
For context, targeted protein degradation (TPD) is a therapeutic approach that uses the body’s own protein disposal system to find and break down harmful proteins that cause disease. Unlike traditional inhibitors, which block activity but leave the protein intact, TPD therapies remove the protein entirely, which makes treatments more effective and longer-lasting.
Pressmaster/Shutterstock.com
Early Phase 1b data in atopic dermatitis patients is expected later this year, and two Phase 2b trials, one in dermatitis and one in asthma, are scheduled to begin in late 2025 and 2026, respectively. Management is also preparing Phase III manufacturing for KT-4621, to ensure scalability at a lower cost.
Kymera Therapeutics Inc. (NASDAQ:KYMR) is developing oral TPD drugs that could provide greater accessibility and convenience as compared to injectable options. The company is advancing a broad pipeline and working with partners such as Sanofi to move its programs through clinical trials, though regulatory approvals remain an important factor.
The company is a consensus Buy, with all analysts covering it assigning a Buy or equivalent rating. The latest one to assert a bullish view was Brian Cheng from JP Morgan, who reaffirmed a Buy rating on August 21 with a price target of $64, implying over 55% potential upside.
Kymera Therapeutics Inc. (NASDAQ:KYMR) is a clinical-stage biopharmaceutical company developing protein degradation therapies for immune and inflammatory diseases and cancer.
While we acknowledge the potential of KYMR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 12 Overlooked Large-Cap Stocks with Low Multiples and 10 Best Stocks for a 20 Year Long-Term Stock Portfolio.
Disclosure: None. This article is originally published at Insider Monkey.
